MONITORFEDGLP-1 CompoundingDec 11, 2025

FDA inspection citations: Nubratori, Inc (3 observations)

FDA cites Nubratori, Inc. for sterile drug production issues.

What changed & why it matters

Med Spa Radar recorded an FDA inspection citation at the federal level, dated December 11, 2025, in the GLP-1 Compounding category.

An inspection citation records what FDA investigators observed at a drug or biologic facility. For an aesthetic practice, the question a citation raises is supplier due-diligence: a cited compounder or outsourcing facility is one whose FDA inspection history is now on the public record.

Type
FDA Inspection Citation
Jurisdiction
Federal
Category
GLP-1 Compounding
Recorded
December 11, 2025

What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.

Firm inspection: Voluntary Action Indicated

This firm’s most recent FDA inspection was classified Voluntary Action Indicated (VAI) — objectionable conditions FDA expects the firm to correct.

Source: FDA Data Dashboard inspection classifications (most recent, by firm FEI).

What to do

Free weekly Brief

Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.

Members get the full “what to do” on every alert — in real time, for your states. Become a member →

FDA Inspection Citation · primary source ↗

Related alerts

Monitoring, not legal advice.